Psychedelic therapy while on antidepressants: what to taper, what not to

Most patients considering psychedelic-assisted therapy are already on an antidepressant. The interactions matter, and they differ sharply by psychedelic and by medication class. This is the practical map.

Important caveat up front: do not make any medication change based on this page or any blog page. Coordinate every taper with your prescribing clinician, because the psychedelic risk is one of several considerations and the depression-relapse risk from dropping an antidepressant can itself be serious.

SSRIs and SNRIs

The most common class of antidepressant. Examples: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), citalopram, paroxetine, venlafaxine, duloxetine.

**With psilocybin, MDMA, LSD:** SSRIs and SNRIs blunt the subjective and likely the therapeutic effect of serotonergic psychedelics. They do not typically block the experience entirely, but the dissociative and therapeutic window is often reduced. Most clinical protocols require a taper plan: typical windows are 2 weeks off short-half-life agents (sertraline, escitalopram, paroxetine, venlafaxine), 4-6 weeks off fluoxetine (long half-life).

**With ketamine (all routes):** ketamine is not a classical serotonergic psychedelic. SSRIs and SNRIs do not blunt it significantly, and tapering is not required for ketamine therapy. This is one of the operational reasons ketamine is the most accessible psychedelic-class option today. If you are deciding between clinic ketamine and an at-home telehealth program, see our [at-home ketamine comparison](/at-home-ketamine) for what each program asks about current antidepressant use at intake.

**The taper itself must be gradual.** Abrupt SSRI/SNRI discontinuation produces a real discontinuation syndrome (flu-like symptoms, brain zaps, mood destabilization) and, for patients with severe depression, a real relapse risk. This is why the taper is coordinated with your prescriber and timed well in advance of the session.

MAOIs

Examples: phenelzine, tranylcypromine, selegiline, isocarboxazid. Also moclobemide (not FDA-approved in the US but prescribed in other countries).

**With psilocybin, MDMA, LSD, ayahuasca: contraindicated.** The combination of an MAOI and a serotonergic agent can produce serotonin syndrome, which is medically serious and has been fatal. This is not a theoretical concern. Any serotonergic psychedelic protocol requires a complete washout from an MAOI before sessions begin - typically 2 weeks for most MAOIs, up to 6 weeks for phenelzine to allow full enzyme regeneration.

**With ketamine:** less dangerous but still cautious. Some programs work with patients on low-dose MAOIs; most defer and taper first. Coordinate with your prescriber.

Lithium

Lithium sits in its own category. Lithium plus psilocybin and related serotonergic psychedelics has been associated with seizures, including in case reports where the patient had a subtherapeutic lithium level. The mechanism is not fully understood but the clinical signal is consistent enough that all credible psilocybin and MDMA protocols exclude lithium.

Lithium plus ketamine is less clear. Some case series have described safe administration, others have described seizure-range events. Most programs ask for a taper or a medication review and consultation with the prescribing psychiatrist before proceeding.

Tricyclic antidepressants

Examples: amitriptyline, nortriptyline, imipramine, clomipramine. Less commonly prescribed in 2026 than in past decades but still in use.

TCAs have serotonergic activity and the combination with psychedelics is cautioned, though the clinical risk picture is less well characterized than MAOIs. Most programs either taper TCAs or work closely with the prescribing clinician.

Atypical antidepressants and augmentation agents

**Bupropion (Wellbutrin):** bupropion is not serotonergic and generally does not blunt psilocybin or MDMA the way SSRIs do. Most programs allow patients to stay on bupropion. Confirm with your clinician.

**Mirtazapine (Remeron):** mixed serotonin/noradrenaline activity. Most programs request tapering or at minimum skip doses around sessions.

**Trazodone:** if used for sleep at low doses, often not a problem. At full antidepressant doses, tapering usually requested.

**Atypical antipsychotics (quetiapine, aripiprazole, olanzapine):** these block 5-HT2A, which is the primary receptor for classical psychedelics. They will substantially blunt or block the experience. Most programs require a taper under psychiatric supervision.

Benzodiazepines, sleep medications, stimulants

Benzodiazepines blunt psychedelic experiences. Most programs ask patients to skip their benzo on the morning of a session. Chronic daily benzodiazepine use requires a conversation with your prescriber.

Stimulants (Adderall, Vyvanse, Concerta) are typically held the day of the session, especially with any compound that raises blood pressure (MDMA, ketamine).

Melatonin and most sleep aids are not a concern.

Cannabis, alcohol and other substances

Cannabis is not contraindicated but can significantly alter the experience. Most programs ask for a 24-48 hour cannabis pause before a session. Alcohol is held the day before at minimum. Kratom, phenibut and novel research chemicals should be disclosed - these are often missed in routine medication reviews.

The bottom line for planning

If you are considering a psilocybin service center session in Oregon or Colorado, an FDA trial, or a provider program: plan 4-8 weeks of lead time with your prescriber to walk through the taper safely. If you are considering ketamine, the medication-review conversation is shorter but still necessary.

Your prescriber does not need to be the one providing the psychedelic service. They do need to know, because the taper and the re-induction on the other side of the session are their job.

Sources

Sarparast A et al., *Drug-drug interactions between psychiatric medications and MDMA or psilocybin*, Journal of Psychopharmacology (2022). Halman A et al., *Drug-drug interactions involving classical psychedelics*, Journal of Psychopharmacology (2024). MAPS Phase 3 protocol documentation on allowed and disallowed concomitant medications. Lykos Therapeutics regulatory submissions.